- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.06. | Innovotech Inc. Announces CFO Transition and Reports 2026 Annual General Meeting Result | 2 | TheNewswire | ||
| 14.05. | Innovotech Inc. Receives Support to Develop Antimicrobial Testing Services and Product Enhancements | 2 | TheNewswire | ||
| 12.05. | Innovotech Inc. Reports Q1 2026 Financial Results and Operational Update | 1 | TheNewswire | ||
| 12.05. | Innovotech reports Q1 results | 1 | Seeking Alpha | ||
| 30.04. | Fendx Technologies Inc (2): Fendx hires Innovotech for Foley regulatory pathway | 8 | Stockwatch | ||
| INNOVOTECH Aktie jetzt für 0€ handeln | |||||
| 30.04. | FendX Technologies Inc.: FendX Engages Innovotech for Regulatory Pathway Assessment of Its Coated Foley Catheter Program | 826 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), a technology company developing surface-protection... ► Artikel lesen | |
| 15.04. | Innovotech Inc. Begins Trading on OTCQB Under Symbol IOTCF, Expanding Access for U.S. Investors | 1 | TheNewswire | ||
| 01.04. | Innovotech Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results | 1 | TheNewswire | ||
| 06.02. | Innovotech Inc: Innovotech appoints McDonald as COO, Szarka as CCO | 2 | Stockwatch | ||
| 05.02. | Innovotech Inc. Strengthens Executive Team and Announces New Edmonton Facility Lease | 1 | TheNewswire | ||
| 27.01. | Innovotech Inc: Innovotech applies for trading on OTCQB | - | Stockwatch | ||
| 26.01. | Innovotech Inc. Announces Intention to Apply for Trading on the OTCQB Venture Market | 1 | TheNewswire | ||
| 26.01. | DealFlow Events: Innovotech Inc. Presenting at the 3rd Annual DealFlow Discovery Conference | 317 | ACCESS Newswire | EDMONTON, AB / ACCESS Newswire / January 26, 2026 / Innovotech Inc. (TSXV:IOT), a leading contract research organization providing proprietary antimicrobial testing and advanced laboratory services... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 75,24 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| QIAGEN | 36,405 | -0,72 % | Dividendenbekanntmachungen (07.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABC ARBITRAGE SA FR0004040608 - 0,04 EUR ACCIONA SA ES0125220311 - 5,7486 EUR AMICA SA PLAMICA00010 2,5 PLN 0,5829 EUR ANY BIZTONSAGI... ► Artikel lesen | |
| ERASCA | 18,530 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| VERA THERAPEUTICS | 42,000 | 0,00 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,250 | 0,00 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| TARSUS PHARMACEUTICALS | 58,13 | -0,02 % | Tarsus Acquires iRenix Medical To Expand Eye Care Pipeline With Late-Stage IRX-101 | ||
| ARCUTIS BIOTHERAPEUTICS | 27,740 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months | FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,64 | -0,01 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| MBX BIOSCIENCES | 61,05 | 0,00 % | MBX Biosciences Aktie erreicht Rekordhoch bei 59,55 USD | ||
| COGENT BIOSCIENCES | 38,880 | +0,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| VOR BIOPHARMA | 19,140 | 0,00 % | Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors | BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 63,44 | 0,00 % | Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 20,360 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering | ZUG, Switzerland, June 23, 2026 - MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and... ► Artikel lesen | |
| BEAM THERAPEUTICS | 32,670 | -0,03 % | BofA bestätigt Kaufempfehlung für Beam Therapeutics nach Schiedsspruch | ||
| ENLIVEN THERAPEUTICS | 51,09 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen |
Das Unternehmen INNOVOTECH INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNOVOTECH INC finden Sie auf Wallstreet Online.